Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 28, 2026

INVESTOR NOTICE: Hercules Capital (HTGC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman

View original at globenewswire.com
INVESTOR NOTICE: Hercules Capital (HTGC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- Hercules Capital (NYSE: HTGC) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise a…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • According to a former Hercules analyst who worked on deal sourcing, Hercules Capital's deal sourcing process amounted to copying investments published on Google Ventures' website

    60% confidence
  • A growing share of Hercules' income is 'phantom' due to its increasing usage of payment-in-kind (PIK) loans that enable borrowers to pay interest by adding to the principal of their debt rather than paying cash interest

    60% confidence
  • Hercules has historically assured investors about the robust origination process for sourcing potential investments and the effectiveness of its due diligence process prior to underwriting investments

    60% confidence
  • Hercules is among the most software-exposed BDCs with approximately 35% of the value of its loan portfolio in software, yet despite billions in such debt falling into distressed territory industry-wide, Hercules still marks its software book at 100 cents on the dollar

    60% confidence
  • Hercules overstated the due diligence in its deal sourcing and loan origination process, overstated the due diligence in its portfolio valuation process, and reported misclassified portfolio investments, resulting in overstated or misrepresented portfolio valuations and NAV

    60% confidence
  • Hagens Berman is investigating Hunterbrook's allegations and, if true, whether Hercules misled investors about its sourcing, underwriting, marks, PIKs, and ultimately its NAV

    60% confidence
  • A former member of Hercules' finance team provided information indicating the team was small and overstretched with few checks in place compared to other BDCs, raising flags about the company's valuation process

    60% confidence
  • Hagens Berman's team has secured more than $2.9 billion in securities and corporate accountability litigation

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
INVESTOR NOTICE: Hercules Capital (HTGC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman — Source | Via News | Finance Via News